NCT03851471 is a EARLY_PHASE1 clinical trial of Jiu-wei-zhen-xiao Granule in Hepatocellular Carcinoma, sponsored by Zhong Wang.

Who is sponsoring NCT03851471?

NCT03851471 is sponsored by Zhong Wang.

What drugs are being tested in NCT03851471?

Interventions in NCT03851471: Jiu-wei-zhen-xiao Granule.

What condition does NCT03851471 study?

NCT03851471 studies Hepatocellular Carcinoma.

Is NCT03851471 still recruiting?

NCT03851471 is currently completed. Last updated 9 April 2021.

Last reviewed 2021-04-09 · How we verify

NCT03851471

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Jiu-wei-zhen-xiao Granule for Advanced Hepatocellular Carcinoma

Completed EARLY_PHASE1 Last updated 9 April 2021

What this trial tests

EARLY_PHASE1 trial testing Jiu-wei-zhen-xiao Granule in Hepatocellular Carcinoma in 10 participants. Completed in 30 March 2021.

Timeline

7 April 2019

Primary endpoint
24 July 2020

30 March 2021

Quick facts

Lead sponsor	Zhong Wang
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	7 April 2019
Primary completion	24 July 2020
Estimated completion	30 March 2021
Sites	1 location across China

Drugs / interventions tested

Jiu-wei-zhen-xiao Granule — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Zhong Wang — full company profile →

Who can join

Adults 18 to 75, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a piolt single-arm trial of Jiu-wei-zhen-xiao Granule, extracted from nine kinds of Chinese medicnie, for the treatment in patients with advanced, unresectable hepatocellular carcinoma(HCC). The primary objective is to assess its therapeutic efficacy in patients with unresectable HCC. The primary endpoint is overall survival (OS) after the use of 12-week drug. Secondary endpoints include progression-free survival (PFS) after the use of 12-week drug, the improvement of the score of the European Organization for Reasearch and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), the changes of the liver function, coagulation function, the size of solid tumors,"Du-tan-yu-jie Zheng" in Chinese medicine, pain Visual Analogue Scale and toxicity profile of Jiu-wei-zhen-xiao Granule.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.
Luo XY, Wu KM, He XX. · · 2021 · cited 144× · PMID 34006331 · DOI 10.1186/s13046-021-01968-w
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.
Fan Y, Xue H, Zheng H. · · 2022 · cited 48× · PMID 35388357 · DOI 10.2147/jhc.s358082

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Zhong Wang trials

Trials by the same sponsor.

NCT06636422 — Post-marketing Safety and Efficacy Surveillance of Motherwort Injection · unknown
NCT04218487 — Xuefu-Zhuyu Capsule for the Treatment of "Qizhi Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome) · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03851471 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhong Wang
Last refreshed: 9 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03851471.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing